The compositions and methods described herein include methods and agents that inhibit inflammasome signaling in a mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s) or other agents. Also described herein are compositions and methods of use thereof for detecting and treating early-stage Alzheimer's disease as well as other inflammatory neurologic conditions.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
The present disclosure, relates, in general to analogs of proline-rich polypeptide 1 (PRP-1) designated tyrosine peptides (TYR peptide) that are useful to treat cancer, such as sarcomas, carcinomas and leukemias or liquid cancers.
The present disclosure relates, in general, to methods for the modulation of a target gene expression by the combined use of nucleic acid based therapeutics targeting complementary gene regulation mechanisms (upNA), leading to desired effects in excess of sum of the effects of each treatment alone, as well as the use of the combinations for the treatment of genetic (e.g., neurological) diseases and disorders associated with aberrant expression of the target gene(s).
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
4.
METHODS AND FORMULATIONS FOR GENE THERAPY, AND FOR COMBINING GENE THERAPY WITH DITPA TREATMENT, OF ALLAN-HERNDON-DUDLEY SYNDROME
The present disclosure is directed to methods of treating Allan-Herndon-Dudley syndrome comprising administering 3,5-diiodothyropropionic acid (DITPA) to a subject in need thereof, and to administering gene therapy to the subject by introducing normal human MCT8 into the subject's cells in order to increase T3 in the subject's brain.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61P 5/14 - Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
The present disclosure is directed to methods of treating Allan-Herndon-Dudley syndrome comprising administering 3,5-diiodothyropropionic acid (DITPA) to a pregnant mother of a prenatal subject in need thereof, and to pharmaceutical DIPTA formulations for administration to the pregnant mother of a prenatal subject in need thereof.
The present subject matter is directed to methods of treating Allan-Herndon-Dudley syndrome comprising administering 3,5-diiodothyropropionic acid (DITPA) to a subject in need thereof, wherein the DITPA administration reduces triiodothyronine ("T3") serum levels to normal, increases T3 brain levels to normal, and maintains normal serum levels of thyroxine (T4) and thyroid stimulating hormone (TSH). The subject may be a child or an adult.
Cannabinoids are a promising and potent class of agents in the management of pain, and preclinical studies in rodent models suggest that cannabinoids may be particularly potent in relieving neuropathic pain. Despite the potential benefits and value of cannabinoids, clinical acceptance has been limited due to CNS side effects at systemic analgesic doses and the fear of misuse potential. What is needed are novel cannabinoid-acting compositions and methods for treating pain. The present disclosure relates to compositions targeting cannabinoid receptors and uses thereof for treating, preventing, and/or mitigating pain.
The present disclosure relates to recombinant polypeptides and uses thereof for treating, preventing, and detecting inflammatory diseases. Specifically, the disclosure provides a recombinant polypeptide comprising an IL-2 polypeptide, a CD25 polypeptide, and an IL- 10 polypeptide, wherein the CD25 polypeptide comprises an extracellular domain of a CD25 protein. In some embodiments, the IL-10 polypeptide is linked to the C-terminus of the CD25 polypeptide.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
C07K 1/00 - General processes for the preparation of peptides
A61P 37/00 - Drugs for immunological or allergic disorders
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Method to measure a visual photosensitivity discomfort threshold or presence of a condition associated therewith within a subject, includes obtaining, by one or more processors, a plurality of images of the subject captured while the at least one pupil and corresponding palpebral fissure contour was being subjected to a light stimuli; determining, by the one or more processors, executing instructions for a neural network having been trained using a plurality of images of a plurality of subjects captured at a plurality of different illumination levels, an output value corresponding to a measure of visual photosensitivity discomfort threshold in which the visual photosensitivity discomfort threshold is defined by an estimated illuminance of the retina of the subject, and outputting, by the one or more processors, the output value in a report.
A61B 3/06 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing colour vision
A61B 3/00 - Apparatus for testing the eyes; Instruments for examining the eyes
A61B 3/14 - Arrangements specially adapted for eye photography
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
10.
NANOMATERIAL-STEM CELL COMPOSITIONS AND METHODS OF USE
Disclosed herein are biocompatible and biodegradable nanomaterials combined with molecules of interest and stem cells in a variety of stable and safe compositions. The nanomaterials comprise poly(ethylene glycol)-oligo(ethylene sulfide) (PEG-OES) amphiphilic block-copolymers that self-assemble in supramolecular aggregates of fibrillar shape. The fibrillar architecture of the assemblies allows the easy, fast and not harmful internalization into stem cells, including the preferred umbilical cord derived mesenchymal stem cells (UC-MSC). The OES core enables loading of hydrophobic molecules, such as imaging agents and drugs, which are carried by the nFIB into the stem cells for a final product that comprises a composition of MSC, nFIB and therapeutic molecule (e.g., MSC-nFIB-Rapamycin). The technology can be utilized to enhance the immunoregulatory potency of MSC via intracellular nanomaterial delivery of immunosuppressive drugs, and to obtain active site-targeting and localized delivery of drug-loaded nanofibrils by exploiting the MSC homing ability.
A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
11.
THERAPEUTIC COMPOSITIONS FOR SKIN DISORDERS AND WOUND REPAIR
Disclosed herein are therapeutics compositions including one or more active agents, for instance a statin, cyclodextrin, or combination thereof. The compositions are useful in the treatment of tissue injuries, including wounds, as well as skin inflammation and infections.
A61K 47/42 - Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
B01J 13/00 - Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
A61L 27/54 - Biologically active materials, e.g. therapeutic substances
A61K 49/18 - Nuclear magnetic resonance (NMR) contrast preparations; Magnetic resonance imaging (MRI) contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
Disclosed herein are novel compounds with STK17A inhibitory activity. The compounds may be used to treat proliferative disorders, including myelodysplastic syndrome and leukemia.
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
An array of inflammatory cytokines are useful as a biomarker useful for detection, diagnosis, and treatment of traumatic brain injury, Inflammatory cytokine cut-off values or cut-off points, ROC, and other characteristics have been determined.
A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
A pharmaceutical composition for use in preventing or treating graft versus host disease (GVHD) in a subject wherein the composition includes intact microvesicles isolated from a biological fluid using polyethylene glycol (PEG) precipitation, wherein administration of the pharmaceutical composition alleviates or prevents one or more symptoms of GVHD in the subject. Also described is a method of preventing or treating graft versus host disease (GVHD) in a subject comprising administering to the subject a pharmaceutical composition comprising intact microvesicles isolated from a biological fluid of an unrelated or related donor using polyethylene glycol (PEG) precipitation wherein one or more symptoms of GVHD comprising weight loss, cutaneous tissue damage, subcutaneous tissue damage, cutaneous inflammation, satellite cell necrosis, truncated lifespan, and/or subcutaneous inflammation are prevented or alleviated in the subject.
UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
UNIVERSITY OF MIAMI (USA)
Inventor
Goldhagen, Brian
Abstract
Methods, systems, and apparatuses are provided for retinal distance-screening using machine learning. Technologies disclosed herein, individually or in combination, provide a sensitive screening tool that utilizes machine learning to identify ocular abnormalities in retinal photos, differentiating normal fundus photos from abnormal fundus photos. Examples of ocular abnormalities that can be identified include diabetic retinopathy, macular degeneration, and glaucoma. Technologies disclosed herein, individually or in combination, can be used as a retinal distance-screening product or can be integrated into existing retinal distance-screening platforms. In some implementations, a list of patients can be obtained, retinal images pertaining to the patients in the list can be designated as either normal or abnormal, and results of such classification can be supplied for further analysis. The technologies described herein can be implemented to pre-screen patients into those that need further assessment by our trained optometrists and those that do not need further assessment.
G06T 5/50 - Image enhancement or restoration by the use of more than one image, e.g. averaging, subtraction
G06T 7/37 - Determination of transform parameters for the alignment of images, i.e. image registration using transform domain methods
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
17.
IL-2 AND TL1A FUSION PROTEINS AND METHODS OF USE THEREOF
The present disclosure relates to chimeric polypeptides and methods of use thereof. The chimeric polypeptides comprise an interleukin-2 (IL-2) peptide; an immunoglobulin peptide; and a TL1 A peptide. The fusion proteins disclosed herein are a major advance and combine both TL1A (the physiologic ligand of TNFRSF25) and IL-2 (the physiologic ligand of CD25). Such a fusion protein can prolong the half-life of IL-2 and allow lower TLI1 levels. Thus, the inventors generated an !L-2-lgG1-TL1A fusion protein and tested its efficacy in vitro and in vivo. In vitro findings demonstrated that both the TL1A and IL-2 FP subunits were functional.
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
18.
METHODS OF ANALYZING SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 2 (STNFR2) AND USES THEREOF
The present disclosure relates to methods of testing immunomodulatory activity of cells, including, for example, mesenchymal stem cells and uses of said cells that are determined as having immunomodulatory activity for treating COVID-19 related acute respiratory distress syndrome (ARDS). Disclosed herein are in vitro methods of evaluating mesenchymal stem cells for their effective immunomodulatory effects in vivo.
Apparatuses and methods for using augmented/mixed reality in surgical settings are provided, and, in particular, apparatuses and methods for intraoperative integration of augmented/mixed reality 3D models with near real-time pathology results. Real-time pathology results are generated using a machine learning analysis of biopsy pathology images in conjunction with a predictive model based on the patient's clinical and demographic data and radiographic imaging data. The apparatuses and methods can be used to provide more accurate intraoperative visualization, tracking, and determination of tumor margins to improve resection extent and any intraoperative or postoperative adjuvant therapy.
The present disclosure relates to methods of silencing expression of genes and uses thereof for treating diseases. Specifically, disclosed herein are Initiation of Transcription GAPmer (INTmers), wherein said INTmers comprise a nucleic acid molecule comprising 14-22 nucleotides, and further wherein said nucleic acid molecule comprises a central core of DNA flanked by RNA on each side.
Devices, systems, and methods for transferring, storing, and/or dispensing a fluid, such as an ocular drug. In one embodiment, a device includes: a first end; and a second end opposite the first end, the first end being configured to be engageable with a secondary reservoir and the second end being configured to release a fluid therefrom. In one embodiment, a method of administering a product includes engaging a secondary reservoir with an engagement assembly at a first end of a device; and delivering a fluid from the secondary reservoir through the engagement assembly and into a chamber of the device to mix with a product within the chamber.
A device, kit, and method for aspirating graft tissue and delivering the graft tissue to a target delivery site. An injector comprises a cylinder and a plunger that is both linearly and rotatably advanceable and retractable within the cylinder. A kit comprises an injector, a cartridge, and a cartridge coupling element that connects the cartridge to the injector. The kit may also include a container that is configured to retain a cartridge and to facilitate connection between the injector and the cartridge. The container includes at least one fluid barrier that prevents spillage of storage solution from the container when the injector is at least partially inserted into the well of the container.
An apparatus for vascular access is described herein. The apparatus can comprise a cart movable from a first location to a second location near a patient, a manipulating device configured to releasably couple a cartridge including a needle, a catheter, and a guidewire that are coaxially disposed with respect to each other, and a robotic arm having a first end mounted to the cart and a second end coupled to the manipulating device. The manipulation device can include a plurality of actuation mechanisms configured to selectively advance the needle, the catheter, and the guidewire when the manipulating device is coupled to the cartridge. The robotic arm can include a plurality of joints that are configured to rotate about a plurality of axes to position the cartridge relative to the arm of the patient such that the needle, the catheter, and the guidewire can be inserted into a target vessel of the patient.
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
24.
OPTIMIZING T CELL DIFFERENTIATION STATE WITH MICRORNAS
THE TRUSTEES OF THE UNIVERSITY OF PENNYSLVANIA (USA)
UNIVERSITY OF MIAMI (USA)
Inventor
Stelekati, Erietta
Wherry, E. John
Fraietta, Joseph A.
Abstract
The current invention includes compositions and methods comprising immune effector cells modified to express miR-29a for the purpose of resisting immune exhaustion.
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
25.
NANOPARTICLES AND USES THEREOF FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS
Bacillus subtilisBacillus subtilis. Also disclosed are methods of preventing or treating a COVID-19 infection comprising providing the SARS-CoV-2 vaccine to a subject.
STING-dependent innate immune signaling pathway activators (STAVs) are delivered to antigen presenting cells in lipid nanoparticle formulations. The range of cancers amenable to STAV therapy can be extended using a non-cell-based nanoparticle strategy that effectively delivers STAV's into the Tumor MicroEnvironment (TME) to potently generate anti-tumor cytotoxic T cell activity. The range of cancers include melanomas and cutaneous T cell lymphomas. The lipid nanoparticles stick to the tumor cells and are co-phagocytosed to activate STING in APC's. Alternatively, the lipid nanoparticles can be introduced through direct inoculation.
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
Disclosed herein are methods for the treatment of Demodex including the step of contacting the Demodex with 5-fluorouracil, or salt thereof. Disclosed herein are ophthalmic compositions including 5-fluorouracil or salt thereof suitable for the treatment of Demodex.
Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human mitochondrial DNA (mtDNA). The disclosure further relates to the use of such recombinant meganucleases in combination with mitochondrial transit peptides in methods for producing genetically-modified eukaryotic cells, and to a population of genetically-modified eukaryotic cells wherein the mtDNA has been modified or edited.
Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human mitochondrial DNA (mtDNA). The disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells, and to a population of genetically-modified eukaryotic cells wherein the mtDNA has been having modified or edited.
Provided herein is a process for preparing a nitrate comprising contacting a nitrogen oxide with a metal oxide under milling conditions to form a nitrate.
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPT. OF VETERANS AFFAIRS (USA)
Inventor
Weintraub, Neal L.
Romero Lucas, Maritza J.
Lucas, Rudolf
Schally, Andrew
Cai, Renzhi
Abstract
Provided herein are compositions and methods of use thereof for the treatment of metabolic disease such as diabetes and obesity. One embodiment provides a method of treating a metabolic disease or syndrome in a subject in need thereof by administering to the subject a therapeutically effective amount of a growth hormone releasing hormone (GHRH) antagonist or a pharmaceutical composition comprising the GHRH antagonist to reduce triglyceride-rich-lipoproteins (TRL) in the subject to treat the metabolic condition or syndrome.
The disclosure provides a method of treating a polyamine imbalance-related disorder. The method comprises administering phenylbutyrate to a subject in need thereof, thereby treating the polyamine imbalance-related disorder.
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
35.
SYSTEMS AND METHODS FOR VISUAL FIELD TESTING IN HEAD-MOUNTED DISPLAYS
Some systems and methods disclosed herein facilitate calibration of a head-mounted display while a visual test is performed. One mechanism of facilitating calibration involves detecting, as a visual test is being performed, that the user's eyes moved in the direction of a displayed stimulus but have not stopped at the point of where the stimulus is displayed, and instead stopped at a different point (e.g., a threshold distance away from the stimulus). Based on that detection, the system may determine that the user has seen the stimulus and that calibration of the sensors is needed. The system may then record that the user has seen the stimulus and perform sensor calibration before displaying the next stimulus.
A61B 3/024 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determining the visual field, e.g. perimeter types
A61B 3/00 - Apparatus for testing the eyes; Instruments for examining the eyes
A61B 3/032 - Devices for presenting test symbols or characters, e.g. test chart projectors
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
G09G 5/38 - Control arrangements or circuits for visual indicators common to cathode-ray tube indicators and other visual indicators characterised by the display of individual graphic patterns using a bit-mapped memory with means for controlling the display position
36.
VISION TESTING VIA PREDICTION-BASED SETTING OF INITIAL STIMULI CHARACTERISTICS FOR USER INTERFACE LOCATIONS
Methods and systems for dynamically determining stimuli characteristics for vision defect determination during a vision test. The methods and systems convert the feedback received from the binary suprathreshold test into a feature input that is provided to a prediction model. The prediction model may be trained to predict non-binary characteristics for sets of locations and confidence scores associated with the sets of locations based on feedback indicating binary characteristics under which users see one or more stimuli presented on user interfaces.
A61B 3/024 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determining the visual field, e.g. perimeter types
A61B 3/02 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient
A61B 3/028 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determination of refraction, e.g. phoropters
A61B 3/06 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing colour vision
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
37.
SMALL MOLECULE INHIBITORS OF CORONAVIRUS ATTACHMENT AND ENTRY, METHODS AND USES THEREOF
Provided herein are small molecule inhibitors of coronavirus attachment and entry, related pharmaceutical compositions, uses, and methods thereof, wherein the compound has a structure of Formula (I):
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
C07C 233/64 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
C07C 233/65 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
The present disclosure relates to a method of treating sensorineural deafness. A method of characterizing hearing loss in a human subject also is provided.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
A novel suction device facilitates periglottic suctioning near the vocal cords (glottis opening) during, for example, laryngoscopy and endotracheal tube intubation. Compared to the existing suction devices (e.g., Yankauer and suction catheters), the shape of the current suction device facilitates placement and maintenance of tip position in the oropharynx. The suction device can suction any fluid (blood, gastric contents, secretions, and aerosol), however, it is specialized to suction aerosol that is generated by the pulmonary system and which emanates from the vocal cords (glottis opening) during laryngoscopy. The catheter suctions through multiple orifices near the tip, oriented toward the glottic opening to maximize evacuation of aerosol.
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
A61B 1/267 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor for the respiratory tract, e.g. laryngoscopes, bronchoscopes
42.
REAGENTS, PHARMACEUTICAL FORMULATIONS, AND METHODS FOR TREATING AND PREVENTING VIRAL INFECTION
This invention provides reagents, pharmaceutical formulations comprising such reagents, and methods for preventing and treating viral infections, specifically coronavirus infections, and in particular infections in humans with COVID-19.
F02K 9/42 - Rocket-engine plants, i.e. plants carrying both fuel and oxidant therefor; Control thereof using liquid or gaseous propellants
F02K 9/72 - Rocket-engine plants, i.e. plants carrying both fuel and oxidant therefor; Control thereof using liquid and solid propellants, i.e. hybrid rocket-engine plants
F02K 9/08 - Rocket-engine plants, i.e. plants carrying both fuel and oxidant therefor; Control thereof using solid propellants
C06B 43/00 - Compositions characterised by explosive or thermic constituents not provided for in groups
44.
DOSIMETRY SYSTEM FOR PHOTODYNAMIC ANTIMICROBIAL THERAPY DEVICE OF INFECTIOUS KERATITIS
Systems and methods for an improved dosimeter for measuring dosage for photodynamic therapy treatment are provided. An example systems includes a dosimeter comprising a variable optical filter system configured to receive a second light, the second light comprising luminescence produced by singlet oxygen and one or more background signal and selectively transmit the luminescence and the one or more background signals as a third light, the variable optical filter system comprises a plurality of optical bandpass filters that are switchable to selectively transmit the luminescence and the one or more background signals. The dosimeter also includes a photoreceiver configured to receive the third light and configured to generate electrical output signals corresponding to the luminescence and the one or more background signals, the electrical output signals being indicative of an amount of the singlet oxygen produced based on activating the photosensitizer.
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using optical sensors, e.g. spectral photometrical oximeters
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventor
Mirsaeidi, Mehdi
Zhang, Chongxu
Schally, Andrew V.
Cai, Renzhi
Tian, Runxia
Abstract
The present disclosure is directed to a method of treating an inflammatory disorder, such as sarcoidosis, using a growth hormone-releasing hormone (GHRH) antagonist.
Compositions and methods for detecting components of the inflammasome in a sample from a subject as markers for inflammasome-related diseases or disorders such as multiple sclerosis, stroke, mild cognitive impairment, Alzheimer's disease, age-related macular degeneration, NASH, inflammaging or traumatic brain injury. Methods of using such inflammasome markers to determine prognosis, direct treatment and monitor response to treatment for the subject with an inflammasome-related disease or disorder such as multiple sclerosis, stroke, mild cognitive impairment, Alzheimer's disease, age-related macular degeneration, NASH, inflammaging or traumatic brain injury are also described.
A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
Hydrodynamic methods for conformally coating non-uniform size cells and cell clusters with biomaterials for implantation, thus preventing immune rejection or inflammation or autoimmune destruction while preserving cell functionality, are disclosed. Further disclosed are reagents, apparatus, and methods for conformally coating cells and cell clusters with hydrogels that are biocompatible, mechanically and chemically stable and porous, with an appropriate pore cut-off size.
Devices, systems, and methods for remotely and, optionally, continuously, reading a temperature of an object, such as a human. In one embodiment, a temperature sensor patch comprises: a sensor circuit, the sensor circuit including: a radiofrequency identification (RFID) chip; and an antenna; and a layer of base material, the sensor circuit being in the layer of material and the layer of base material being configured to permit a signal transfer between the sensor circuit and a surrounding environment.
The compositions and methods described herein include methods and agents that inhibit inflammasome signaling in a mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s) or other agents. Also described herein are compositions and methods of use thereof for treating viral-associated lung inflammation, for example lung inflammation associated with viral infections such as SARS-CoV-2.
Systems and methods for assessing, monitoring, or theranosing a condition or disorder based on a comparison of limb stability for one or more limbs of a subject from a baseline. The method includes placing two or more inertial measurement sensors on the limbs of the subject, acquiring baseline limb excursion data from the inertial measurement sensors while a patient is performing at least one of a static balance activity and a dynamic balance activity by tracking the relative displacement of the respective two or more inertial measurement sensors; acquiring post-injury limb excursion data after an injury from the inertial measurement sensors while a patient is performing at least one of a static balance activity and a dynamic balance activity; and determining the activity clearance index as a function of a comparison of the baseline limb excursion data compared to the post-injury limb excursion data.
A tissue processing chamber is disclosed. The tissue processing chamber includes at least one rotary blade housed within a tissue chamber and a drive shaft coupled to the rotary blades. Rotation of the drive shaft rotates the rotary'· blades and presses a tissue sample through a screen adjacent to the at least one rotary blade, wherein rotation of tire at least one rotary blade presses processed tissue through the screen. The tissue processing device also includes a collection chamber coupled to the tissue chamber configured to collect the processed tissue.
B02C 18/30 - Mincing machines with perforated discs and feeding worms
B02C 18/06 - Disintegrating by knives or other cutting or tearing members which chop material into fragments; Mincing machines or similar apparatus using worms or the like with rotating knives
B02C 18/08 - Disintegrating by knives or other cutting or tearing members which chop material into fragments; Mincing machines or similar apparatus using worms or the like with rotating knives within vertical containers
Embodiments of an improved photodynamic therapy device are provided. An example of the device includes an irradiation head having a first end and a surface at a second end, the surface having a radius of curvature. The device also includes a plurality of light sources disposed on the curved surface. The plurality of light sources are configured to emit light having at least one wavelength corresponding approximately to an excitation peak of at least one photosensitizer. The light emitted by the plurality of light sources is focused to a focal point based on the radius of curvature of the surface and a target surface (e.g., a corneal surface of an eye) may be positioned at the focal point for treatment.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
Ion booster for thrust generation. The invention pertains to electrical propulsion generated by the rapid acceleration of ions between asymmetrical electrodes. The invention is applicable for propulsion generation in atmospheric and space environments.
A microfluidic structure includes a first media channel or well and a second media channel. A removable membrane is provided between the first media channel or well and the second media channel to permit diffusion. One or more plates is used to form the second media channel. A method of creating a microenvironment using the microfluidic structure is also provided.
Disclosed herein are topical formulations of cannabidiol, such as nanoparticulate cannabidiol, methods of making such compositions, and their use in treating autoimmune diseases and disorders, e.g., alopecia areata.
The present invention provides an expression vector, host cells, methods and kits for the treatment or prevention of a coronavirus infection in a subject.
System for combined intraoperative aberrometry and optical coherence tomography (OCT). In an embodiment, the system comprises an OCT system, an aberrometer, a beam delivery system, and a beam splitter. The beam delivery system is configured to output a beam towards a target, wherein the beam has an outward path to the target and a return path after being reflected by the target. The beam splitter is positioned in the return path of the beam and configured to split the return path into a first path to the OCT system and a second path to the aberrometer. Thus, the OCT system and aberrometer can share a single beam delivery system.
A61B 3/00 - Apparatus for testing the eyes; Instruments for examining the eyes
A61B 3/117 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for examining the anterior chamber or the anterior chamber angle, e.g. gonioscopes
A device to assist in percutaneous punctures. In an embodiment, the device comprises an upper component, a lower component, a coupling mechanism that couples the lower component to the upper component, and a tool holder. The upper component comprises a platform configured to support a medical instrument comprising a needle, and the lower component comprises one or more finger holes, wherein each of the one or more finger holes is configured to receive a human finger therethrough. The tool holder is configured to hold a tool at a position that, when the platform is supporting the medical instrument, is on an opposite side of a tip of the needle as the lower component.
The disclosure relates to a plurality of cells, compositions and methods for identifying modulators of a target protein. The cells, compositions and methods comprise a (i) a target domain gene (ii) an intracellular chimeric G-protein alpha subunit comprising an endogenous G-protein alpha subunit with a humanized C-terminus; and (iii) an inducible reporter, wherein the expression of the reporter is dependent on the activation of the target domain encoded by target domain gene, and wherein the target domain gene comprises a barcode. The disclosure further relates to a host cell comprising a plurality of exogenous landing pads integrated in the host cell's genome, wherein each exogenous landing pad is integrated at a safe harbor genome loci in the host cell's genome.
This disclosure relates to systems, compounds and methods for stem cell delivery. More specifically, the disclosure relates a system for promoting tissue regeneration, the system comprising a plurality of stem cells coated with at least one or a plurality of dendrimer nanocarriers that specifically bind to an adhesion molecule. Additionally, the disclosure relates to methods for delivering stem cells to damaged or diseased tissue for stem cell regeneration of the tissue.
A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 43/00 - Drugs for specific purposes, not provided for in groups
63.
MATERIALS AND METHODS FOR EXTRACELLULAR VESICLE DETECTION
Described herein is a method for detecting the presence of circulating extracellular vesicles in a subject. The method comprises contacting a biological sample from the subject with an antibody mimetic that specifically binds to a cell surface marker on the vesicles, wherein the antibody mimetic is coupled to a detectable label; and detecting presence of extracellular vesicles in the sample by detecting the presence of the detectable label coupled to the antibody mimetic bound to the vesicles.
Embodiments of multichannel vaginal cylinder systems and methods for high dose rate brachytherapy of gynecologic cancers are provided. A brachytherapy delivery system according to an embodiment comprises a cylinder structure comprising a proximal portion that abuts patient tissue when in a deployed state, a slot along a central longitudinal axis for receiving a tandem, and at least one channel. The at least one channel comprises a longitudinal segment extending longitudinally from an opening in a distal base of the cylinder structure toward the proximal portion, and a terminal segment extending at least partially transversely along the proximal portion. A radiation source can be positioned at one or more discrete positions within the at least one channel from a first position posterior to the slot to a second position anterior to the slot, when in the deployed state.
Ocular photosensitivity analyzer. In an embodiment, a programmable light source, comprising a plurality of multi-spectra light modules, is configured to emit light according to a lighting condition. For one or a plurality of iterations, the programmable light source is activated to emit the light according to the lighting condition, and collect a response, by a subject, to the emitted light via a sensing system comprising one or more sensors. Between iterations, the programmable light source may be reconfigured based on the response to determine a visual photosensitivity threshold of the subject.
This disclosure relates generally to compositions of carbon dots, doxorubicin, and transferrin and methods for use of the same in the treatment of DLBCL tumors.
The present disclosure generally relates to methods for preparing human mesenchymal stem cells (hMSCs) that express high CD10 phenotypes. The present disclosure further relates to methods of treating local inflammation, fibrosis, and/or musculoskeletal pain using hMSCs that express high CD10 phenotypes. This invention provides methods for producing clinically relevant amounts of MSCs that do not involve FBS or other animal-derived media, supplements, or components, wherein the MSCs produced thereby can be more safely used for treating appropriate diseases and disorders in humans and other animals.
Stereotactic frame holder. In an embodiment, the stereotactic frame holder comprises a shoulder base, a floating base, and a coupling mechanism that couples the shoulder base to the floating base while providing translational control such that a distance between the shoulder base and the floating base can be adjusted. The shoulder base may define a first interior space that is configured to receive at least a neck of a patient, and the floating base may define a second interior space, which is aligned with the first interior space and is configured to receive at least a neck of a patient. In addition, the floating base may be configured to support a stereotactic frame.
This disclosure relates generally to orally administrable nanoparticle for treating and preventing viral infection, specifically ZIKA and coronavirus infections. Methods for using the orally administrable nanoparticle are also provided for treating and preventing viral disease.
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 17/02 - Peptides being immobilised on, or in, an organic carrier
A61K 9/52 - Sustained or differential release type
Additive manufacturing of composites with short-fiber reinforcement. In an embodiment, an extrusion channel is supplied with a composite ink comprising short fibers, and the composite ink is extruded out of a material outlet of the extrusion channel, while vibrating the extrusion channel and the material outlet by one or more vibration motors along one or more vibration axes, to fabricate a three-dimensional composite structure. The short fibers may comprise milled carbon fibers having an average length of 50 μm or less and an average aspect ratio of 4.5 or less, and the composite ink may comprise a high fiber volume ratio (e.g., 27+%). Despite analytical models that predict otherwise, the composite structures, resulting from disclosed embodiments, have enhanced strength.
C12Q 1/60 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving cholesterol
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
Quantification of symmetry and repeatability in limb motion for treating abnormal motion patterns. In the context of gait analysis, gait data may be acquired as signals from inertial sensors (e.g., gryoscopes). Each signal represents an angular velocity of a lower limb segment of a subject during ambulation. Each signal may be segmented into stride signals, and a gait metric may be calculated based on the stride signals. The gait metric may comprise a symmetry metric that represents a similarity of the stride signals across two signals acquired for at least one pair of contralateral limb segments. Additionally or alternatively, the gait metric may comprise a repeatability metric that represents a similarity of the stride signals within a signal. In other embodiments, other types of sensors may be used and/or motion data may be acquired and metrics calculated for other types of motions and/or for upper limb segments.
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 5/103 - Measuring devices for testing the shape, pattern, size or movement of the body or parts thereof, for diagnostic purposes
A63B 21/00 - Exercising apparatus for developing or strengthening the muscles or joints of the body by working against a counterforce, with or without measuring devices
A63B 24/00 - Electric or electronic controls for exercising apparatus of groups
73.
METAL-OXIDE NANOPARTICLES, PHOTOCATALYTIC NANOSTRUCTURES, AND RELATED METHODS
Artificial intelligence for evaluating patient distress using facial emotion recognition. In an embodiment, an artificial intelligence model is applied to facial image(s) of a patient to classify each facial image into one of a plurality of emotional states based on a facial expression in the facial image. A determination may be made as to whether or not to alert a healthcare provider based on the emotional state(s) into which the facial image(s) were classified. If a determination is made to alert a healthcare provider, a notification may be transmitted to the healthcare provider.
G06K 9/66 - Methods or arrangements for recognition using electronic means using simultaneous comparisons or correlations of the image signals with a plurality of references, e.g. resistor matrix references adjustable by an adaptive method, e.g. learning
G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
G06K 9/00 - Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints
75.
SYSTEM AND METHOD FOR AI-BASED EYE CONDITION DETERMINATIONS
In some embodiments, a set of eye images related to a subject may be provided to a prediction model. A first prediction may be obtained via the prediction model, where the first prediction is derived from a first eye image and indicates whether an eye condition is present in the subject. A second prediction may be obtained via the prediction model, where the second prediction is derived from a second eye image and indicates that the eye condition is present in the subject. An aspect associated with the first prediction may be adjusted via the prediction model based on the second prediction's indication that the eye condition is present in the subject. One or more predictions related to at least one eye condition for the subject may be obtained from the prediction model, where the prediction model generates the predictions based on the adjustment of the first prediction.
A61B 3/00 - Apparatus for testing the eyes; Instruments for examining the eyes
A61B 3/14 - Arrangements specially adapted for eye photography
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
Device for arterial puncture assistance. In an embodiment, the device comprises an upper component, lower component, and coupling mechanism that couples the lower component to the upper component. The upper component may comprise a platform configured to support a syringe. The lower component may comprise one or more finger holes, wherein each of the one or more finger holes is configured to receive a human finger therethrough, so as to enable contemporaneous stabilization of the lower component on the human finger and palpation of an arterial pulse by the human finger during an arterial puncture.
A61B 90/11 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges for stereotaxic surgery, e.g. frame-based stereotaxis with guides for needles or instruments, e.g. arcuate slides or ball joints
A61M 5/315 - Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod; Appliances on the rod for facilitating dosing
77.
GHRH ANTAGONISTS FOR USE IN A METHOD OF TREATING SARCOIDOSIS
Systems and devices for temporarily disabling an assailant or other target using disabling flashes of light from a light-emitting device. A tactical lighting system also includes protective eyewear that is paired with the light-emitting device and configured to shutter in synchronization with the pattern of disabling light flashes to protect the wearer's eyes while disabling an assailant or other target.
UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF VETERANS AFFAIRS (USA)
UNIVERSITY OF MIAMI (USA)
Inventor
Mirsaeidi, Mehdi
Zhang, Chongxu
Abstract
The disclosure relates to a sarcoidosis animal model and methods of inducing sarcoidosis in an animal. The disclosure also related to methods of producing an in vitro granuloma, and methods of using the sarcoidosis animal model. Disclosed herein are animals comprising one or more granulomas, wherein the one or more granulomas comprise Mycobacterium abscessus cell wall microparticles.
A system for electrohydromodulation of wastewater. In an embodiment, the system comprises an anode in contact with at least one anodic chamber and a cathode in contact with a cathodic chamber. Each anodic chamber and the cathodic chamber are configured to receive a flow of wastewater. A first multivalent cation exchange membrane, between each anodic chamber and the cathodic chamber, allows multivalent cations to pass therethrough while preventing monovalent ions to pass therethrough. A power source is electrically coupled to each anode and the cathode, and is configured to apply a voltage across wastewater in the anodic chamber and the cathodic chamber, to thereby cause multivalent cations in the wastewater to pass through the multivalent cation exchange membrane.
H04N 19/44 - Decoders specially adapted therefor, e.g. video decoders which are asymmetric with respect to the encoder
H04N 19/593 - Methods or arrangements for coding, decoding, compressing or decompressing digital video signals using predictive coding involving spatial prediction techniques
G06K 9/36 - Image preprocessing, i.e. processing the image information without deciding about the identity of the image
81.
METHODS OF DESIGNING NOVEL ANTIBODY MIMETICS FOR USE IN DETECTING ANTIGENS AND AS THERAPEUTIC AGENTS
1212122. Also provided herein are computer-readable storage media having stored thereon machine-readable instructions executable by a processor and systems. Related methods of manufacturing a clamp peptide and the clamp peptides manufactures by the methods are provided.
A steerable guide. In an embodiment, the steerable guide comprises a needle, a shaft, a spring housing, and a translational screw. The needle comprises a wire tube and a wire configured to curve the needle when retracted relative to the wire tube. The wire tube is connected to the distal end of the shaft, and the wire is connected to the distal end of the spring housing. The screw extends into a cavity within the shaft, and is configured to move along a longitudinal axis. A spring is positioned within the cavity, between the proximal end of the spring housing and the distal end of the screw. Thus, when the screw moves in the proximal direction while a position of the spring housing is fixed by the wire, the spring is compressed between the proximal end of the spring housing and the distal end of the translational screw.
The present disclosure relates to a method of treating sensorineural deafness. The disclosure provides a method of treating sensorineural deafness in a mammalian subject (e.g., human) in need thereof. The method comprises administering to a subject having a mutation in a CLDN9 gene a composition that comprises a polynucleotide that encodes a CLDN9 peptide, a CLDN9 peptide, an agent that blocks expression of a mutant CLDN9 gene, an agent that corrects the mutation in the CLDN9 gene.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventor
Kapiloff, Michael S.
Li, Jinliang
Abstract
The present invention provides a method of treating heart failure with reduced ejection fraction, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the anchoring of PP2A to mAKAPß. This composition is preferably in the form of a viral based gene therapy vector that encodes a fragment of mAKAPß to which PP2A binds.
The present disclosure relates to methods of detecting and treating inherited neuropathy. In various aspects, the method comprises detecting the presence of a mutation in the sorbitol dehydrogenase (SORD) gene in a sample from a subject. In various embodiments, th SORD mutation is a DNA variant classified as pathogenic or likely pathogenic according to American College of Medical Genetics and Genomics (ACMG) criteria.
C12N 9/00 - Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
86.
IMPROVED INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME
Disclosed herein are inhibitors of the Notch transcriptional activation complex, and methods for their use in treating or preventing diseases, such as cancer. The inhibitors described herein can include compounds of Formula (I) and pharmaceutically acceptable salts thereof: Formula (I), wherein the substituents are as described.
The invention relates to a vector and/or vaccine that can be used for therapeutic and preventive purposes. The virus is based on vesicular stomatitis virus (VSV) with a substituted VSV G (glycoprotein) for HTLV-1 G, referred to as gp62. The vector and/or vaccine further comprise a fusion protein comprising HTLV-1 regulatory proteins (HBZ and TAX) together to make a fusion product (HBZ-TAX) and mutated versions thereof. The vector and/or vaccine do not impede innate immune signaling and generate neutralizing antibodies and CTLs to gp62, HBZ, and TAX.
In certain embodiments, vision defect information may be generated via a dynamic eye-characteristic-based fixation point. In some embodiments, a first stimulus may be displayed at a first location on a user interface based on a fixation point for a visual test presentation. The fixation point for the visual test presentation may be adjusted during the visual test presentation based on eye characteristic information related to a user. As an example, the eye characteristic information may indicate a characteristic of an eye of the user that occurred during the visual test presentation. A second stimulus may be displayed during the visual test presentation at a second interface location on the user interface based on the adjusted fixation point for the visual test presentation. Vision defect information associated with the user may be generated based on feedback information indicating feedback related to the first stimulus and feedback related to the second stimulus.
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
A61B 3/00 - Apparatus for testing the eyes; Instruments for examining the eyes
A61B 3/14 - Arrangements specially adapted for eye photography
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A system for ophthalmic imaging comprising an ophthalmic device configured to obtain stereoscopic images of an eye of a patient and to transmit the images in real-time to a display device via a network for viewing by practitioners. The ophthalmic device comprises at least an optic assembly, a processing assembly, a slit assembly, such as a slit lamp, and a positioning assembly. Control devices structured to control the ophthalmic device over the network, such as the world wide web, can be disposed at a plurality of locations, and may be remote from the ophthalmic device while providing real time control of the parameters of the ophthalmic device by the practitioner(s) associated therewith.
A61B 3/14 - Arrangements specially adapted for eye photography
A61B 3/00 - Apparatus for testing the eyes; Instruments for examining the eyes
A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
G02B 30/22 - Optical systems or apparatus for producing three-dimensional [3D] effects, e.g. stereoscopic images by providing first and second parallax images to an observer’s left and right eyes of the stereoscopic type
A lateral flow assay device for testing a biological sample includes housing, a sample receiving pad, a conjugate test pad, and a nitrocellulose membrane. The sample receiving pad and conjugate test pad, as well as the nitrocellulose membrane, are enclosed within an interior portion of the housing. The sample receiving pad is in fluid communication with an opening defined in an outer surface of the housing for receiving the biological sample. At least a portion of the conjugate test pad is in contact with the sample receiving pad and is configured to test the biological sample. At least one window is defined in the outer surface of the housing adjacent the conjugate test pads such that the results of the test performed on the conjugate test pads are visible from outside of the housing.
UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
UNIVERSITY OF MIAMI (USA)
Inventor
Jackson, Andrew
Schally, Andrew, V.
Cai, Renzhi
Cai, Xianyang, Zhang
Wang, Haibo
Sha, Wei
Abstract
Described herein are compositions and methods for treating pulmonary fibrosis and cancer. The compositions include growth hormone releasing hormone peptides. The methods include reducing lung inflammation, lung scarring, reducing expression of T cell receptor complex genes as well as inhibiting tumor growth.
The present disclosure relates to a methods of using an IL-2/CD25 fusion protein in combination with at least one neo-antigen for promoting anti-tumor immunity in a subject of need. The disclosure further provides a method of treating cancer. The method comprises administering to mammalian subject a therapeutically effective amount of an IL-2/CD25 fusion protein in combination with at least one neo-antigen.
A61P 35/04 - Antineoplastic agents specific for metastasis
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
95.
SYSTEMS AND METHOD FOR DETECTING COGNITIVE IMPAIRMENT
Systems, methods, and computer readable media for determining cognitive impairment (CI) in patients are provided herein. Various regional structural-functional parameters of the retina can serve as biomarkers for the detection of CI. The method can include forming a database including a quantification of retinal structure and retinal function of a plurality of eyes associated with a plurality of patients, providing a baseline cognitive impairment (CI) reference. The method can include determining a measure of functionality of neurons in the retina based on an electroretinogram (ERG) of a patient. The method can include determining a structural measure of the first retina based on a generalized dimension spectrum and singularity spectrum of the skeletonized retinal image, and a lacunarity parameter of the skeletonized retinal image. The method can include determining a level of cognitive impairment based on the structural and functional measures.
Systems and methods provide a parallelized deep learning approach to spectral fitting for magnetic resonance spectroscopy data enabling accurate and rapid spectral fitting and determination of metabolite measurements using a conventional computer. The method may include processing multi-spectra magnetic resonance (MR) spectroscopy data of a region of interest through a series of neural networks. The method may include determining baseline components of each spectrum using a first neural network of the series, generating baseline-corrected components for each spectrum using the baseline components; and determining one or more peak components of each spectrum using a second neural network of the series and the baseline-corrected components. The method may further include determining one or more metabolite measurements of the one or more metabolites in the region of interest using the one or more peak components.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
THE UNIVERSITY OF MIAMI (USA)
Inventor
Kapiloff, Michael S.
Goldberg, Jeffrey L.
Abstract
Nervous system trauma and neurodegeneration including in optic neuropathies are treated by administration of an effective dose of a PDE4D3 displacing agent to promote neurite extension, neuroprotection and recovery. In some embodiments the neurons are optic neurons, including without limitation retinal ganglion cells (RGCs). A cAMP signaling compartment restricted by mAKAPα-anchored PDE4D3 directly regulates neuronal phenotype, and can be molecularly manipulated with therapeutic effect.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present disclosure provides materials and methods for analyzing a chromatin sample. In one aspect, described herein is a method of analyzing a chromatin sample, the method comprising adding a biotin-labeled non-mammalian DNA and an anti-biotin antibody to a sample comprising chromatin fragments, wherein the biotin-labeled DNA and the antibiotin antibody form a complex in the sample; immunoprecipitating a target binding protein in the sample with an antibody that binds the target binding protein; reverse crosslinking of DNA bound to the target binding protein and disassociating the non-mammalian DNA bound to biotin; and purifying the DNA of step (c).
The disclosure provides an expression vector (e.g., AAV vector) comprising a nucleic acid sequence encoding (1) the heavy and/or light chain of an antibody and (2) one or more shRNA sequences targeting fucosyltransferase-8 (FUT8).
The present disclosure is directed to methods for determining responsiveness to cell therapy in a subject suffering from a cardiovascular disorder (e.g., cardiomyopathy) and methods of treating subjects suffering from a cardiovascular disorder.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
patents
